漢達生技

漢達生技 https://validator.w3.org/feed/docs/rss2.html 重大訊息-本公司因近期股價價格異常，應櫃買中心要求公布相關資訊，俾便投資人暸解 Material Information- (Supplemental Announcement of Material Information on August 6, 2026) Announcement of the newly appointed Chief Business Officer 重大訊息- (補充公告115/08/06重大訊息)公告本公司新任商務長 Material Information- The Company has been required by TPEx to announce the financial data according Material Information- Announcement of the Board’s Resolution to release the non-competition restriction on managerial officers 重大訊息-本公司董事會通過解除經理人競業禁止之限制案 Material Information- Announcement of the Board’s Resolution to Repurchase Treasury Shares 重大訊息-公告本公司董事會決議買回庫藏股事宜 Material Information- Announces on behalf of the subsidiary Handa Oncology, LLC, regarding FDA’s denial of the Citizen Petition against 505(b)(2) new drug HND-039 Omcazio 重大訊息-代子公司Handa Oncology, LLC公告與505(b)(2)新藥HND-039 Omcazio有關之訴願案，已由美國FDA駁回 Material Information- Announces on Behalf Handa Oncology, LLC, regarding the 505 (b)(2) new formulation drug HND-039 OMCAZIO receives U.S. FDA Final Approval (FA) 重大訊息-代子公司 Handa Oncology, LLC 公告治療癌症之505(b)(2) 新藥 HND-039 OMCAZIO 通過美國FDA新藥藥證審查，取得最終核准(Final Approval) Material Information- Announcement of the newly appointed Chief Business Officer Material Information- Announcement of the Board’s Resolution to release the non-competition restriction on managerial officers 企業社會責任重大訊息-本公司董事會通過解除經理人競業禁止之限制案 HOME Material Information- Regarding the 505(b)(2) new formulation drug HND-039 Omcazio patent infringement litigation has been voluntarily dismissed by the plaintiff Material Information- Announcement of the Board’s Resolution to redeem and cancel treasury shares for a capital reduction and the record date 重大訊息-公告本公司及代子公司Handa Pharma, Inc.及Handa Oncology, LLC 505(b)(2)新藥HND-039 Omcazio美國專利侵權訴訟已由原告自行撤回訴訟 Material Information- Announcement of the Completion of Registration for Capital Reduction through Cancellation of Treasury Shares 重大訊息-公告本公司辦理庫藏股註銷減資變更登記完成沿革與里程碑 Financials 財務資訊重大訊息-公告本公司新任商務長重大訊息-公告本公司董事會決議註銷庫藏股暨訂定減資基準日 Material Information- Announcement on behalf of Handa Pharma, Inc. Increase captial to Handa Oncology, LLC History 重大訊息-代重要子公司Handa Pharma,Inc.公告100%投資Handa Oncology, LLC Material Information- Announcement of the Board of Directors approved the consolidated financial statements for 2026 Q2. 重大訊息-公告本公司董事會通過115年第二季合併財務報告 Material Information- The Company was invited to attend the in-person and virtual institutional investor conference hosted by First Securities 重大訊息-本公司受邀參加第一金證券舉辦之實體暨線上法人說明會 OMCAZIO TM 法說會資訊誠信經營獨立董事與內部稽核主管及會計師之溝通情形 Material Information- Announces on Behalf Handa Oncology, LLC, regarding the 505 (b)(2) new formulation drug HND-039 OMCAZIO receives U.S. FDA Tentative Approval (TA) OMCAZIO TM HND-027 Phyrago® Phyrago ® 重大訊息-代子公司 Handa Oncology, LLC 公告治療癌症之505(b)(2) 新藥 HND-039 OMCAZIO 取得美國 FDA 暫時性許可(Tentative Approval, TA) Material Information- Announcement of the expected date of the Board Meeting to approve 2026 Q2 Financial Report on August 6, 2026 重大訊息-公告本公司115年第二季財務報告董事會預計召開日期為115年8月6日公司治理執行情形 Material Information- Correction to Handa Pharmaceuticals, Inc., and on behalf of the subsidiary, regarding the 505(b)(2) new formulation drug HND-039 patent infringement lawsuit 重大訊息-更正公告本公司及代子公司Handa Pharma, Inc.及Handa Oncology, LLC公告505(b)(2)新藥HND-039美國專利訴訟案之相關文書案號首頁